Nike initiated with a Buy at Goldman Sachs 04:48 NKE Goldman Sachs analyst Kate McShane initiated coverage of Nike with a Buy rating and $172 price target. The analyst sees a "healthy industry backdrop with a company-specific continued focus on innovation to drive growth." Nike has room to expand its direct-to-consumer initiative, which should drive higher gross margins over time, McShane tells investors in a research note. In addition, its high cash balance should enable additional investment and capital return to shareholders. Sourcing concerns are transitory and likely priced in following the recent selloff, contends McShane.
Amyris call volume above normal and directionally bullish 15:45 AMRS Bullish option flow detected in Amyris with 4,255 calls trading, 1.0x expected, and implied vol increasing almost 5 points to 79.58%. 11/26 weekly 16 calls and Oct-21 12.5 calls are the most active options, with total volume in those strikes near 2,000 contracts. The Put/Call Ratio is 0.12. Earnings are expected on November 4th.

AC approval 'an important milestone' for Ocular's pipeline, says Piper Sandler 15:26 OCUL Piper Sandler analyst Joseph Catanzaro notes that Ocular Therapeutix announced FDA approval of Dextenza's sNDA for the treatment of ocular itching associated with allergic conjunctivitis.
While the immediate commercial impact from this label is likely modest, it has important downstream implications for Ocular's front of the eye intracanalicular pipeline, the analyst contends. Catanzaro also notes that the AC label represents Dextenza's formal move
into the office setting and will allow Ocular to prime the anterior segment market around the potentially favorable reimbursement dynamics with using an intracanalicular insert, namely procedure fees and buy-and-bill that
could provide significant economic incentives for physicians and their offices. Along these lines Phase IIb dry eye data for OTX-CSI are
expected this quarter and will be another significant catalyst for Ocular and the potential for its future front of the eye business, he adds. The analyst has an Overweight rating and a price target of $27 on the shares.